My current responsibilities include the design and development of work that is highly confidential, competitive, and proprietary, and as such, is limited in the context of an online portfolio. Please contact me for information on work and to view additional samples and case studies.




























Add ezetimibe to statin therapy and pull ahead. Way ahead.





























It's about protection.

There are few sights more heart-rending than a suffering baby. A baby hospitalized with severe RSV infection is particularly tragic because, in many cases, the suffering is preventable.

If your baby was born early, he or she may be at risk during the next RSV season (November through April in most areas of the country)> Fortunately, there is a medication available that can prevent RSV disease and can be given right in your pediatrician's office.

Don't ignore the threat of RSV. Call your pediatrician or the RSV hotline at 1-877-633-4441. If your baby was born early, call now – before it's too late.



er partner in RSV protection





A preemie's lungs: ticket for a return visit to the ICU.


Premature birth interrupts normal lung development, putting infants at high risk for severe RSV disease. Preterm delivery is associated with altered airway development, even in the absence of neonatal respiratory distress. In these infants, lung function remains significantly reduced even at one year of age.1 As as result, infants born prematurely (< 35 weeks gestational age) are at a significant risk for severs R5Vdisease.1-3


Synagis® (palivizumab) is indicated for the prevention of severe RSV disease in infants at high risk. In the landmark IMpact-RSV trial, Synagis® reduced RSV hospitalizations by 55% compared with placebo (p < 0.001). The most common adverse events potentially related to Synagis® were upper respiratory infection, otitis media, rhinitis, and rash. Rare cases of anaphylaxis (< 1 per 100,000) have been reported following re-exposure to Synagis*.*

- References
 1. Hoo.A-F. Dezateux C., Hernehen M., et al. J Podute. 2002. (5):652-658.
 2. Hjalmsson, O., Sunfleng K. Am J Rogio Grit Gare Mod., 2002. 165:93-67.
 3. Marcell AE, Driscoll JM, James LS, J Podute. 1967; 110(2):111-115.
 4. The Myata-Key Vasuly Croup Podusios. 1969; 10(2):531-537.

Please see full prescribing information on following page



























My current responsibilities include the design and development of work that is highly confidential, competitive, and proprietary, and as such, is limited in the context of an online portfolio. Please contact me for information on work and to view additional samples and case studies.

jeff.pienkos@gmail.com 732.614.3652 mobile | 732.758.9354 residence pinkpixelproductions.com